Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen ItSeeking Alpha • 05/06/26
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock UpZacks Investment Research • 05/06/26
Sales of Novo Nordisk's New Weight-Loss Pill Are Off To a Strong Start. The Stock Is RisingInvestopedia • 05/06/26
Novo Nordisk Pops As Wegovy Pill Doubles Sales Expectations In Its First QuarterInvestors Business Daily • 05/06/26
Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history.Market Watch • 05/06/26
Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026GlobeNewsWire • 05/06/26
Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominanceCNBC • 05/04/26
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?Zacks Investment Research • 05/04/26
'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report findsCNBC • 05/04/26